Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Uğur Uslu(Parker Institute for Cancer Immunotherapy), Carl H. June(Parker Institute for Cancer Immunotherapy)
Cited by 61
Related Papers
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
|JCI Insight|2018|279
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
|JCI Insight|2018|196
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells
|Proceedings of the National Academy of Sciences|2023|77
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
|Nature Communications|2024|50